Related references
Note: Only part of the references are listed.Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies
S. B. Park et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Assessment of nerve excitability in toxic and metabolic neuropathies
Arun V. Krishnan et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2008)
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis
Steve Vucic et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
Stephanie R. Land et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neurons
Anthony M. Rush et al.
JOURNAL OF PHYSIOLOGY-LONDON (2007)
Neuroprotection during chemotherapy - A systematic review
Melanie Walker et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2007)
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer
Andreas A. Argyriou et al.
ACTA ONCOLOGICA (2007)
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients
Wei-Shu Wang et al.
ONCOLOGIST (2007)
Axonal conduction and injury in multiple sclerosis: the role of sodium channels
Stephen G. Waxman
NATURE REVIEWS NEUROSCIENCE (2006)
Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding
Lauren E. Ta et al.
NEUROTOXICOLOGY (2006)
Oxaliplatin and axonal Na+ channel function in vivo
Arun V. Krishnan et al.
CLINICAL CANCER RESEARCH (2006)
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
Thierry Lecomte et al.
CLINICAL CANCER RESEARCH (2006)
High-throughput identification of IMCD proteins using LC-MS/MS
T Pisitkun et al.
PHYSIOLOGICAL GENOMICS (2006)
The pathophysiology of oxaliplatin-induced neurotoxicity
Matthew C. Kiernan et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels
RG Webster et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability
MC Kiernan et al.
BRAIN (2005)
Oxaliplatin-induced neurotoxicity and the development of neuropathy
AV Krishnan et al.
MUSCLE & NERVE (2005)
Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish
MC Kiernan et al.
ANNALS OF NEUROLOGY (2005)
The effects of mexiletine on excitability properties of human median motor axons
S Kuwabara et al.
CLINICAL NEUROPHYSIOLOGY (2005)
Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain
JA Black et al.
PAIN (2004)
Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy
RJ Lehky et al.
MUSCLE & NERVE (2004)
Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE
MJ Craner et al.
BRAIN (2004)
Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions:: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer
L Gamelin et al.
CLINICAL CANCER RESEARCH (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
J Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Oxaliplatin-related side effects: Characteristics and management
J Cassidy et al.
SEMINARS IN ONCOLOGY (2002)
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs
MJ McKeage et al.
BRITISH JOURNAL OF CANCER (2001)
Excitability of human axons
D Burke et al.
CLINICAL NEUROPHYSIOLOGY (2001)
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
F Maindrault-Goebel et al.
ANNALS OF ONCOLOGY (2000)
The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons
H Adelsberger et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Grading of chemotherapy-induced peripheral neuropathy
TJ Postma et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
